551. Enhanced Cell Killing Effect of E1 Modified Adenoviruses Expressing HSV-TK Suicide Gene

Kang, Yoon-A; Ko, Dong Hyun; Kim Kim, Jaesung; Lee, Young-Sook; Kwon, Oh-Joon; Sohn, Joo Hyuk; Yun, Chae-Ok; Kim, Joo-Hang
June 2005
Molecular Therapy;Jun2005, Vol. 11, p213
Academic Journal
An abstract of the article "Enhanced Cell Killing Effect of E1 Modified Adenoviruses Expressing HSV-TK Suicide Gene," by Yoon-A Kang, Dong Hyun Ko, Jaesung Kim Kim, Young-Sook Lee, Oh-Joon Kwon, Joo Hyuk Sohn, Chae-Ok Yun, Joo-Hang Kim is presented.


Related Articles

  • Topical antiviral ointment may treat adenoviral conjunctivitis. Biro, Ashley // Primary Care Optometry News;Jan2013, Vol. 18 Issue 1, p6 

    The article reports on a clinical trial to investigate whether ganciclovir such as Zirgan can prevent the spread of adenovirus, a common cause of acute follicular conjunctivitis, and reduce the number of days of viral shedding.

  • Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy. Amalfitano, Andrea; Parks, Robin J. // Current Gene Therapy;May2002, Vol. 2 Issue 2, p111 

    One of the major hurdles to successful gene therapy of genetic and / or acquired disease is the ability to efficiently introduce a foreign gene into the tissue of interest and, in the case of some genetic diseases, achieve long-term expression of the transgene. Due to their ability to transduce...

  • Clinical Trials with Oncolytic Adenovirus in China. Wang Yu; Hu Fang // Current Cancer Drug Targets;Mar2007, Vol. 7 Issue 2, p141 

    Since the 1990s, oncolytic viruses were utilized to treat cancer patients from phase I to phase III. Oncolytic virus development in China has been keeping in step with that in other countries and even accelerated the process in some fields, especially in conducting clinical trials. H101 is one...

  • Trials and tribulations.  // Nature Genetics;Mar2000, Vol. 24 Issue 3, p201 

    Comments on the debate about a clinical trial on gene therapy since the death of a man from a large dose of adenoviral vector. Trial of dose-escalation design; Increase of the levels of circulating factor IX; Reduction of the episodes of factor infusion.

  • Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). Peiperl, Laurence; Morgan, Cecilia; Moodie, Zoe; Li, Hongli; Russell, Nina; Graham, Barney S.; Tomaras, Georgia D.; De Rosa, Stephen C.; McElrath, M. Juliana // PLoS Clinical Trials;Oct2010, Vol. 7 Issue 10, Special section p1 

    Background: Individuals without prior immunity to a vaccine vector may be more sensitive to reactions following injection, but may also show optimal immune responses to vaccine antigens. To assess safety and maximal tolerated dose of an adenoviral vaccine vector in volunteers without prior...

  • Immune Response Explains Poor Result for Vaccine Trial. Kingman, Sharon // BioWorld Today;11/25/2009, Vol. 20 Issue 228, p1 

    The article focuses on the investigation on the results of a STEP trial involving human immunodeficiency virus (HIV) vaccination. It recounts that the trial suggested that a vaccine to protect against HIV infection led to a higher susceptibility to HIV infections in the vaccinated group than in...

  • A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Trudel, Suzane; Trachtenberg, John; Toi, Ants; Sweet, Joan; Zhi Hua Li; Jewett, Michael; Tshilias, John; Li Hue Zhuang; Hitt, Mary; Yonghong Wan; Gauldie, Jack; Graham, Frank L.; Dancey, Janet; Stewart, A. Keith // Cancer Gene Therapy;Oct2003, Vol. 10 Issue 10, p755 

    Preclinical studies demonstrate that intratumoral delivery of adenovirus expressing IL-2 eradicates pre-established tumors in mice and confers immune protection from rechallenge. To explore the activity of AdCAIL-2 in prostate cancer, a Phase I clinical trial was conducted in patients with...

  • Titer determination of Ad5 in blood: a cautionary note. Cichon, G; Boeckh-Herwig, S; Kuemin, D; Hoffmann, C; Schmidt, H H; Wehnes, E; Haensch, W; Schneider, U; Eckhardt, U; Burger, R; Pring-Akerblom, P // Gene Therapy;Jun2003, Vol. 10 Issue 12, p1012 

    Recombinant adenoviruses are presently the most efficient in vivo gene transfer system available. Targeting single organs or large tumors by adenoviral vectors requires an intravascular route of application. During the first pass of viral particles through the vascular bed of the target tissue,...

  • Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Davidoff, Andrew M.; Gray, John T.; Ng, Catherine Y.C.; Zhang, Youbin; Zhou, Junfang; Spence, Yunyu; Bakar, Yusura; Nathwani, Amit C. // Molecular Therapy;Jun2005, Vol. 11 Issue 6, p875 

    Abstract: A detailed comparison of recombinant adeno-associated viral (rAAV) vectors of serotypes 2, 5, and 8 was performed in mice and nonhuman primates. Differences within the capsid proteins and viral terminal repeats of rAAV-2 and -5 did not significantly influence their ability to transduce...


Read the Article


Sign out of this library

Other Topics